Not to be administered to patients w/ type 1 DM. Consider use only when diet & exercise therapies, which are the basis of treatment of DM, were thoroughly used, but were not sufficiently effective. Periodically check renal function & sufficiently monitor course in treatment of patients w/ renal impairment. Patients at risk for vol depletion (whose plasma glucose is controlled poorly, concomitantly using diuretics). UTI & genital infections. Ketoacidosis. +ve urinary glucose during administration. Macrovascular outcomes. Patients using other antidiabetic drugs (particularly sulfonylureas, insulin prep or GLP-1 receptor agonists). May interfere test results of urinary glucose & serum 1,5-AG assay. Not to be administered to patients w/ severe renal impairment or end-stage renal failure being treated by dialysis. Hepatic & moderate renal impairment. Patients who work in high places; may affect ability to drive &/or use machines. Pregnancy & lactation. Childn. Elderly.
Sign Out
